SEC EDGARJUN 182 min read$WGS

Stueland Katherine sold $638K of WGS

Stueland Katherine (CHIEF EXECUTIVE OFFICER) sold 10,501 shares of GeneDx Holdings Corp. (WGS) at an average of $60.77 ($59.75–$61.50, $0.64M total) across 3 trades on 2026-06-16.

Original reporting

SEC EDGAR · Stueland Katherine

Published Jun 18, 2026, 4:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 6, 2026, 11:54 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$WGS

Neutral

medium confidence

Mentioned

$WGS

Relevance

5/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$WGSNeutralLow

Why it matters

The only new information is the disclosed open-market sale details and the CEO’s remaining share count; there is no accompanying guidance, deal, or regulatory development.

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a durable repricing without other catalysts.

What to watch

The article notes no pre-arranged 10b5-1 plan, but it does not provide context on motivation, other concurrent insider trades, or whether future sales follow.

Relevance 5/10Novelty 3/10Timing: filed 2026-06-18, discloses sale executed 2026-06-16

Background

The article is a SEC Form 4 insider transaction disclosure for GeneDx Holdings Corp. (WGS) by its CEO.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$WGSNeutralMedium confidence

Context

CEO Katherine Stueland sold about 10,501 shares of GeneDx Holdings (WGS) in an open-market transaction totaling $638,104.42.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only unless follow-on filings or company news emerge.

Evidence & confidence

The filing discloses the sale size, price range, and post-transaction holdings, but provides no new operational, financial, or regulatory information about WGS.

Market effects

Sector

Minimal; insider sales do not typically reset sector expectations without additional company-specific news.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, so the signal may be weak.

Key entities

issuer
GeneDx Holdings Corp.
Company whose CEO reported an open-market sale of shares via SEC Form 4.
insider
Katherine Stueland
Chief Executive Officer who sold shares totaling $638,104.42 across three trades on 2026-06-16.

Read at source ← All news

AUG 3

$PLTRMed

After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR

Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.

investing.com6 min

AUG 3

$WGSHighAI 9/10

GeneDx Holdings Corp. (WGS): Results of Operations and Financial Condition

GeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026pressrele.htm EX-99.1 Document Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of

SEC EDGAR 8-K6 min

JUL 28

$WGSMed

GeneDx’s $4.8M AI-Hype Settlement Exposes Governance Failures -By Fransiscus Nanga Roka

GeneDx Holdings (formerly Sema4, NASDAQ: WGS) and former officers filed responses in a federal securities class action over alleged overstated capabilities of Centrellis, an AI-molecular and phenotypic data system. The parties settled for about $4.8M to resolve claims of fraud tied to a 2022 GeneDx acquisition valued near $623M. Court filings were submitted July 24, 2026.

opinionnigeria.com5 min

JUL 18

$WGSMed

GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check said a securities-fraud class action was filed against GeneDx Holdings Corp. (NASDAQ: WGS) in the District of Connecticut. The class period runs April 16, 2025 to May 4, 2026, with an Aug. 3, 2026 lead-plaintiff deadline. Allegations center on statements about the viability of GeneDx’s up-to-$51 million acquisition of Fabric Genomics and a May 4, 2026 impairment write-off of $31.3 million.

prnewswire.com4 min

JUN 8

$WGSLowAI 8/10

Casdin Capital, LLC purchased $11.1M of WGS (indirect holdings)

Casdin Capital, LLC purchased 200,000 indirectly-held shares of GeneDx Holdings Corp. (WGS) at an average of $55.55 ($52.86–$56.44, $11.11M total) across 2 trades over 2026-06-04 to 2026-06-05.

SEC EDGAR2 min

JUN 4

$WGSMedAI 9/10

GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSS

GeneDx Holdings (NASDAQ: WGS) shares fell 49% on May 5, 2025 after the company reported a Q1 2026 earnings miss, a tenfold increase in net loss, and cut full-year 2026 guidance by 12%, according to the report. Hagens Berman opened a securities-law investigation, citing a shift in product mix and reduced growth expectations. The article notes ARR was $3,750 in 2025 and was expected to be flat for 2026.